NEW DELHI, April 20, 2015 /PRNewswire/ --
- Development of a Novel Taxane and a PI3K Targeting Supramolecular Therapeutic Using the VOLVOX Platform - To be Presented on Tuesday, Apr 21, 8:00 AM EST
- Supramolecular Assembly of Antibody-drug Conjugates Using an anti-HER2 Monoclonal Antibody and Camptothecin as Cytotoxic Payload - Presented on Sunday, Apr 19, 1:00 PM EST
Invictus Oncology Private Limited, a leader in supramolecular therapeutic program, today announced that the company's novel computational platform technology (VOLVOX) for designing anti-cancer supramolecular therapeutics, and the CORDLink technology platform for designing Antibody Drug Conjugates (ADCs) will be presented at the American Association for Cancer Research (AACR) annual meeting being held in Philadelphia, PA, April 18-22.
Supramolecular therapeutics are next generation treatments for cancer that enhance anti-tumor efficacy with improved side-effect profiles. The VOLVOX platform merges big data modeling with drug design in silico to predict the optimal supramolecular structures.
In another approach, a unique linker (CORDLink) platform technology based on a novel coordination linker chemistry has been successfully used to generate supramolecular assembly of antibody-drug conjugates maintaining the integrity of the antibody without impacting binding to the target. ADCs allow the specific delivery of the anti-cancer payload to the tumor.
Development of a novel taxane and a PI3K targeting supramolecular therapeutic using the VOLVOX platform
Title: A novel computational platform technology (VOLVOX™) for designing anticancer supramolecular therapeutics
Poster Presentation: Tuesday, Apr 21, 8:00 AM EST
Abstract Number: 3687
Presenter: Prithvi Raj Pandey, Ph.D., Invictus Oncology, New Delhi, India
Supramolecular assembly of antibody-drug conjugates using an anti-HER2 monoclonal antibody and camptothecin as cytotoxic payload
Title: Supramolecular assembly of antibody-drug conjugates using CORDLink platform for targeted drug delivery
Poster Presentation: Sunday, Apr 19, 1:00 PM EST
Abstract Number: 649
Presenter: Nimish Gupta, Invictus Oncology, New Delhi, India
Both these abstracts can be viewed on the AACR website, www.aacr.org.
About Invictus Oncology Private Limited
Invictus Oncology is a privately held cancer chemotherapeutics company dedicated towards providing cancer patients a better quality of life by developing new generation cancer drugs with better efficacy and less toxicity. A breakthrough discovery at Harvard involving the use of nanotechnology-based strategies to destroy cancer cells led to the conception of Invictus Oncology. The company was co-founded in 2011 by Dr. Raghunath Mashelkar and Dr. Shiladitya Sengupta and is based in Delhi. With an outstanding team of internationally acclaimed scientists and ground-breaking science, the new drug from Invictus is set to revolutionize cancer therapy by being the first anti cancer drug developed in India for global impact. For more information, visit www.invictusoncology.com .
Invictus Oncology Private Limited
SOURCE Invictus Oncology Private Limited